FAYUVI rebisufligene etisparvovec Updated Nov 5
With the approval binary behind it, FAYUVI's investor focus shifts to commercial execution: Q4 2026 and early 2027 revenue disclosures, payer reimbursement decisions, and the number of patients dosed. The stock's 52-week range ($12.73-$39.89) and recent cost-cutting plan suggest the market is pricing in execution risk. Watch for early revenue signals from the Q4 2026 earnings report and any updates on treatment center activations.
- First and only FDA-approved treatment for Sanfilippo syndrome type A, a fatal childhood disease with no prior disease-modifying options, giving it a monopoly position in an ultra-rare indication with 3,000-5,000 patients in the US.
- List price of $3.95 million per one-time dose positions it as a potential blockbuster if even a small fraction of eligible patients are treated, and the company received a $203 million Priority Review Voucher upon approval.
- Ultragenyx is targeting GAAP profitability in 2027, with Q3 2026 total revenue of $173 million, and FAYUVI plus the earlier gene therapy GENGLYCOS represent new revenue streams beyond the established CRYSVITA franchise.
- At $3.95 million list price, commercial adoption faces significant payer access hurdles; ultra-rare gene therapies often see slow uptake as insurers negotiate outcomes-based contracts and treatment centers must be certified.
- The drug was rejected by the FDA in 2025 due to manufacturing problems, highlighting manufacturing risk for complex gene therapies, and the open-label single-arm trial design (no placebo control) leaves some efficacy uncertainty.
- Ultragenyx recently cut 20% of its workforce, discontinued the GTX-102 Angelman syndrome program, and saw multiple analyst downgrades in September 2026 (JP Morgan, William Blair, Evercore, Baird), reflecting pipeline and commercial concerns.